Business
Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
NEW YORK and SAVONA, Italy, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a
About this update from Tilray Brands, Inc.
[{"type":"text","content":"NEW YORK and SAVONA, Italy, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (\"Tilray\") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a strategic update to its medical cannabis operations in Italy with the launch of Tilray Medical Italia, the new name of the entity previously known as FL Group. The transition to Tilray Medical Italia reflects the Company’s continued commitment to building a unified, scalable medical cannabis platform across Europe, while strengthening its presence in one of the region’s most important regulated medical markets. Tilray Medical Italia is expanding its footprint in Italy through a growing portfolio of medical cannabis products authorized by the Italian Ministry of Health and supported by a partnership with Molteni Farmaceutici, one of Italy’s leading pharmaceutical companies with deep experience serving hospitals, physicians, and pharmacies across the country. Rajnish Ohri, President International at Tilray Brands, stated, “Italy remains a strategically important market for Tilray Medical as we continue to build a leading, regulated medical cannabis platform across Europe. The launch of Tilray Medical Italia strengthens our local presence, aligns our operations under a single global medical brand, and reinforces our long-term commitment to supporting patients, physicians, and healthcare systems with high-quality, authorized medical cannabis products.” Strengthening a Regulated Medical Cannabis Platform in Italy Tilray Medical Italia operates within Italy’s established medical cannabis framework, supplying products authorized by the Ministry of Health and distributed through hospital and pharmacy channels in accordance with national regulations. The Company’s Italian operations are supported by Tilray’s broader European medical infrastructure, including pharmaceutical-grade cultivation, manufacturing, quality assurance, and regulatory expertise developed across multiple federally legal medical cannabis markets. Through its partnership with Molteni, Tilray Medical Italia continues to support physician education, responsible prescribing, and patient access, while maintaining rigorous standards for p...